Brivaracetam for the treatment of focal-onset seizures: pharmacokinetic and pharmacodynamic evaluations

References

• Beghi E. The Epidemiology of Epilepsy. Neuroepidemiology. 2020;54(2):185–191.
   Google Scholar
• Shneker BF, Fountain NB. Epilepsy. Dis Mon. 2003;49(7):426–478.
   Google Scholar
• de Biase S, Valente M, Gigli GL, et al. Pharmacokinetic drug evaluation of lacosamide for the treatment of partial-onset seizures. Expert Opin Drug Metab Toxicol. 2017;13(9):997–1005.
   Google Scholar
• Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883–890.
   Google Scholar
• Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78(20):1548–1554.
   Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–1015.
   Google Scholar
• de Biase S, Nilo A, Bernardini A, et al. Timing use of novel anti-epileptic drugs: is earlier better? Expert Rev Neurother. 2019;19(10):945–954.
   Google Scholar
• US FDA. BRIVIACT ® (brivaracetam): highlights of prescribing information. [cited 2020 May 16]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205836s005,205837s004,205838s003lbl.pdf
   Google Scholar
• European Medicines Agency. Brivaracetam: summary of product characteristics. [cited 2020 May 16]. Available from: https://www.ema.europa.eu/en/documents/product-information/briviact-epar-product-information_en.pdf
   Google Scholar
• Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57(4):538–548.
   Google Scholar
• Crowder KM, Gunther JM, Jones TA, et al. Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci U S A. 1999;96(26):15268–15273.
   Google Scholar
• Wasterlain CG, Suchomelova L, Matagne A, et al. Short-term and long-term effects of brivaracetam in an animal model of status epilepticus. Epilepsia. 2009;50(Suppl. 10):13.
   Google Scholar
• Wang L, Zhou X, Shi J, et al. Overexpression of synaptic vesicle protein 2A inhibits seizures and amygdaloid electroencephalogram activity in pilocarpine-induced pharmacoresistant epileptic rats. Neuropsychiatry. 2018;8(2):595–605.
   Google Scholar
• Rogawski MA, Bazil CW. New molecular targets for antiepileptic drugs: alpha(2)delta, SV2A, and K(v)7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep. 2008;8(4):345–352.
   Google Scholar
• Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.
   Google Scholar
• Yang X, Bognar J Jr., He T, et al. Brivaracetam augments short-term depression and slows vesicle recycling. Epilepsia. 2015;56(12):1899–1909.
   Google Scholar
• Wood MD, Gillard M. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2017;58(2):255–262.
   Google Scholar
• Ge YX, Lin YY, Bi QQ, et al. Brivaracetam prevents the over-expression of synaptic vesicle protein 2A and rescues the deficits of hippocampal Long-term potentiation in vivo in chronic temporal lobe epilepsy rats. Curr Neurovasc Res. 2020 May 14.
   Google Scholar
• Niespodziany I, Rigo JM, Moonen G, et al. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons. Epilepsia. 2017;58(11):e157–e161.
   Google Scholar
• Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol. 2018;10:1–22.
   Google Scholar
• Makke Y, Abou-Khalil B. Brivaracetam efficacy and safety in focal epilepsy. Expert Rev Neurother. 2019;19(10):955–964.
   Google Scholar
• Mumoli L, Palleria C, Gasparini S, et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;111:85–141.
   Google Scholar
• Nicolas JM, Tytgat D, Matagne A, et al. High brain permeability differentiates brivaracetam from levetiracetam and reveals promising potential as acute intervention against prolonged and life threatening seizures. Epilepsy Curr. 2014;14(S1):224.
   Google Scholar
• Wasterlain CG, Baldwin R, Naylor DE, et al. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia. 2011;52(Suppl. 8):70–71.
   Google Scholar
• Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63(6):680–688.
   Google Scholar
• Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy males. Br J Clin Pharmacol. 2008;66(1):71–75.
   Google Scholar
• Otoul C, Watanabe S, McCabe S, et al. Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/mL Oral Solution and 50-mg Film-Coated Tablet. Clin Pharmacol Drug Dev. 2017;6(3):313–317.
   Google Scholar
• Hulhoven R, Scheen A, Watanabe J, et al. Bioavailability and safety of the intravenous administration of brivaracetam. Epilepsia. 2008;49(Suppl. 7):438.
   Google Scholar
• Stockis A, Hartstra J, Mollet M, et al. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57(8):1288–1293.
   Google Scholar
• Klein P, Biton V, Dilley D, et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 2016;57(7):1130–1138.
   Google Scholar
• Chanteux H, Kervyn S, Gerin B, et al. In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction unrestricted brain permeability. Epilepsy Curr. 2015;15(Suppl.1):2.310.
   Google Scholar
• Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209.
   Google Scholar
• Hannestad J, Finnema SJ, Mercier J, et al. Brivaracetam enters the human brain faster than levetiracetam. Epilepsia. 2016;57(Suppl. 2):128.
   Google Scholar
• Milovanović JR, Janković SM, Pejčić A, et al. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother. 2017;18(13):1381–1389.
   Google Scholar
• Sargentini-Maier ML, Espie P, Coquette A, et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36(1):36–45.
   Google Scholar
• Stockis A, Watanabe S, Rouits E. et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinetic. 2014;29(5):394–399.
   Google Scholar
• Product monograph. BRIVLERA® (brivaracetam). [cited 2020 May 16]. Available from: https://www.ucb-canada.ca/_up/ucbpharma_ca_en/documents/Brivlera%20PM%20Oct%2030-18-E.pdf
   Google Scholar
• Sargentini-Maier ML, Homery MC, Stockis A. Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects. Epilepsia. 2008;49(Suppl. 7):452.
   Google Scholar
• Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017;73(6):727–733.
   Google Scholar
• Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52(12):1927–1933.
   Google Scholar
• Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013;53(6):633–641.
   Google Scholar
• Hoy SM. Brivaracetam: a review in partial-onset (focal) seizures in patients with epilepsy. CNS Drugs. 2016;30(8):761–772.
   Google Scholar
• Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83(1):1–43.
   Google Scholar
• Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.
   Google Scholar
• Stockis A, Sargentini-Maier ML, Brodie MJ. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration. Epilepsy Res. 2016;128:163–168.
   Google Scholar
• Brodie MJ, Fakhoury T, McDonough B, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program. Epilepsy Res. 2018;145:55–62.
   Google Scholar
• Klotz KA, Hirsch M, Heers M, et al. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60(7):e74–e77.
   Google Scholar
• Moseley BD, Chanteux H, Nicolas JM, et al. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163:106327.
   Google Scholar
• Schoemaker R, Wade JR, Stockis A. brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol. 2016;56(12):1591–1602.
   Google Scholar
• Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016;44(6):792–799.
   Google Scholar
• Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia. 2014;55(3):e27–e31.
   Google Scholar
• Stockis A, Rolan P. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol. 2013;53(12):1313–1321.
   Google Scholar
• Kruithof AC, Watanabe S, Peeters PA, et al. Pharmacological interactions between brivaracetam and ethanol in healthy males. J Psychopharmacol. 2016;31(7):915–926.
   Google Scholar
• French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–525.
   Google Scholar
• Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.
   Google Scholar
• Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.
   Google Scholar
• Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.
   Google Scholar
• Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and Generalized epilepsies results of a phase III, double-blind, randomized, placebo-controlled, flexible- dose trial. Epilepsia. 2014;55(1):38–46.
   Google Scholar
• Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898.
   Google Scholar
• Ben-Menachem E, Mameniškienė R, Quarato PP, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314–323.
   Google Scholar
• Moseley BD, Sperling MR, Asadi-Pooya AA, et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three Phase III studies. Epilepsy Res. 2016;127:179–185.
   Google Scholar
• Lattanzi S, Cagnetti C, Foschi N, et al. Brivaracetam add-on for refractory focal epilepsy: A systematic review and meta-analysis. Neurology. 2016;86(14):1344–1352.
   Google Scholar
• Feyissa AM. Brivaracetam in the treatment of epilepsy: a review of clinical trial data. Neuropsychiatr Dis Treat. 2019;15:2587–2600.
   Google Scholar
• Asadi-Pooya AA, Sperling MR, Chung S, et al. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: a post-hoc study. Epilepsy Res. 2017;131:70–75.
   Google Scholar
• Benbadis S, Klein P, Schiemann J, et al. Efficacy, safety, and tolerability of brivaracetam with concomitant lamotrigine or concomitant topiramate in pooled phase III randomized, double-blind trials: A post-hoc analysis. Epilepsy Behav. 2018;80:129–134.
   Google Scholar
• Villanueva V, López-González FJ, Mauri JA, et al. BRIVA-LIFE-A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand. 2019;139(4):360–368.
   Google Scholar
• Steinig I, von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany. Epilepsia. 2017;58(7):1208–1216.
   Google Scholar
• Steinhoff BJ, Bacher M, Bucurenciu I, et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy - A monocenter survey. Seizure. 2017;48:11–14.
   Google Scholar
• Schubert-Bast S, Willems LM, Kurlemann G, et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89–93.
   Google Scholar
• Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59(8):1549–1556.
   Google Scholar
• Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):1027–1034.
   Google Scholar
• Kälviäinen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57(2):210–221.
   Google Scholar
• Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals. Epilepsy Behav. 2017;70(Pt A):177–181.
   Google Scholar
• Aicua-Rapun I, André P, Rossetti AO, et al. Intravenous brivaracetam in status epilepticus: correlation between loading dose, plasma levels and clinical response. Epilepsy Res. 2019;149:88–91.
   Google Scholar
• Santamarina E, Parejo Carbonell B, Sala J, et al. Use of intravenous brivaracetam in status epilepticus: A multicenter registry. Epilepsia. 2019;60(8):1593–1601.
   Google Scholar
• Klein P, Tyrlikova I, Brazdil M, et al. Brivaracetam For The Treatment Of Epilepsy. Expert Opin Pharmacother. 2016;17(2):283–295.
   Google Scholar
• Zhu LN, Chen D, Chen T, et al. The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials. Seizure. 2017;45:7–16.
   Google Scholar
• Rosillon D, Astruc B, Hulhoven R, et al. Effect of brivaracetam on cardiac repolarisation - a thorough QT study. Curr Med Res Opin. 2008;24(8):2327–2337.
   Google Scholar
• Khaleghi F, Nemec EC 2nd. Brivaracetam (Briviact): A Novel Adjunctive Therapy for Partial-Onset Seizures. P T. 2017;42(2):92–96.
   Google Scholar
• Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165–168.
   Google Scholar
• Russo E, Citraro R, Mula M. The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy. Expert Opin Drug Discov. 2017;12(11):1169–1178.
   Google Scholar
• Brigo F, Bragazzi NL, Nardone R, et al. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure. 2016;42:29–37.
   Google Scholar
• Arnold S, Badalamenti V, Diaz A, et al. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase III studies. Epilepsy Res. 2018;141:73–82.
   Google Scholar
• Brigo F, Lattanzi S, Nardone R, et al. Intravenous Brivaracetam in the Treatment of Status Epilepticus: A Systematic Review. CNS Drugs. 2019;33(8):771–781.
   Google Scholar